# The Role of Positive Klebsiella Culture in Revision Hip and Knee Arthroplasty

**Authors:** Vinzenz Bussek, Marion T. Tödtling, Jennyfer A. Mitterer, Veronika Achatz, Selma Tobudic, Jochen G. Hofstaetter

PMC · DOI: 10.3390/pathogens15020164 · 2026-02-03

## TL;DR

This study examines the role of Klebsiella in joint infections following hip and knee surgeries, finding it is rare but often linked to complex, chronic cases with poor outcomes.

## Contribution

The study provides new insights into the clinical significance and treatment challenges of Klebsiella-associated periprosthetic joint infections.

## Key findings

- Klebsiella spp. was identified in 1.0% of culture-positive revision joint surgeries, predominantly in chronic and polymicrobial infections.
- Klebsiella pneumoniae showed high resistance to cephalosporins and penicillin but remained susceptible to meropenem, gentamicin, and levofloxacin.
- Outcomes were generally poor, with many patients requiring further intervention or classified as Tier 4 (death).

## Abstract

Gram-negative (GN) periprosthetic joint infections (PJIs) are being increasingly reported. However, the role of Klebsiella species in PJIs remains unclear. Therefore, we aimed to analyze the prevalence, clinical presentation, microbial spectrum, antibiogram, treatment strategies and outcomes of Klebsiella-associated PJIs. A total of 1925 culture-positive total joint revision arthroplasties (rTJA) were retrospectively reviewed at a single center. Patient data were extracted from our institutional arthroplasty and PJI database. We identified 20 Klebsiella-positive PJIs (hip/knee, 11/9), representing 1.0% of all culture-positive rTJAs. The cases were predominantly polymicrobial (80%) and chronic (50%). Notably, Klebsiella spp. was rarely detected as an initial infectious event but was predominantly identified in the context of revision or re-revision procedures, frequently in patients with prior or persistent PJIs. Klebsiella pneumoniae was the most frequent species, with 44% showing multi-drug resistance. The antimicrobial susceptibility of Klebsiella isolates showed high resistance to cephalosporines and penicillin, in contrast little to no resistance to meropenem, gentamicin and levofloxacin. The most common initial surgical intervention was a two-stage revision (65%). Infection control (Tier 1) was observed in 11%, while further intervention was needed in 56% (Tier 3). All patients who had already died were classified as Tier 4 (33%). Klebsiella spp. was detected in 10.0% of GN rTJAs and was mainly associated with complex revision settings rather than primary infections. It is often associated with chronic polymicrobial infections and high antimicrobial resistance. The outcomes were generally poor, highlighting the need for pathogen-specific treatment strategies and improved diagnostics.

## Linked entities

- **Chemicals:** penicillin (PubChem CID 2349), meropenem (PubChem CID 441130), gentamicin (PubChem CID 3467), levofloxacin (PubChem CID 149096)
- **Species:** Klebsiella pneumoniae (taxon 573)

## Full-text entities

- **Genes:** Extended-spectrum beta-lactamase [NCBI Gene 13982007]
- **Diseases:** PJI (MESH:D057068), GP (MESH:D016908), injury to (MESH:D014947), Charlson Comorbidity (MESH:D004194), Klebsiella (MESH:D007710), PJI (MESH:C537702), bacterial infections (MESH:D001424), GN (MESH:D016905), septic (MESH:D001170), fungal (MESH:D009181), infectious (MESH:D003141), ICM (MESH:D000082122), polymicrobial infections (MESH:D060085), Death (MESH:D003643), Infection (MESH:D007239)
- **Chemicals:** levofloxacin (MESH:D064704), cefepime (MESH:D000077723), meropenem (MESH:D000077731), gentamicin (MESH:D005839), Fusidic acid (MESH:D005672), Methicillin (MESH:D008712), saline (MESH:D012965), teicoplanin (MESH:D017334), doxycycline (MESH:D004318), amoxicillin-clavulanic acid (MESH:D019980), polysaccharide (MESH:D011134), ciprofloxacin (MESH:D002939), daptomycin (MESH:D017576), cefazolin (MESH:D002437), Trimethoprim-sulfamethoxazole (MESH:D015662), beta-lactam (MESH:D047090), -lactamases (-), penicillin (MESH:D010406), ceftazidime/avibactam (MESH:C000595613), Cefuroxime (MESH:D002444), piperacillin-tazobactam (MESH:D000077725), Ceftriaxone (MESH:D002443), trimethoprim (MESH:D014295), cephalosporins (MESH:D002511), linezolid (MESH:D000069349), dalbavancin (MESH:C469289), rifampicin (MESH:D012293), fluoroquinolones (MESH:D024841)
- **Species:** Klebsiella species [taxon 2885105], Enterococcus faecalis (species) [taxon 1351], aureus [taxon 46170], Cutibacterium acnes (species) [taxon 1747], Candida albicans (species) [taxon 5476], Citrobacter koseri (species) [taxon 545], Escherichia coli (E. coli, species) [taxon 562], Pseudomonas aeruginosa (species) [taxon 287], Klebsiella pneumoniae (species) [taxon 573], Lodderomyces parapsilosis (species) [taxon 5480], Klebsiella oxytoca (species) [taxon 571], Bacteria Latreille et al. 1825 (Bacteria stick insect, genus) [taxon 629395], Staphylococcus aureus (species) [taxon 1280], Staphylococcus epidermidis (species) [taxon 1282], Homo sapiens (human, species) [taxon 9606], Proteus mirabilis (species) [taxon 584]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12943718/full.md

---
Source: https://tomesphere.com/paper/PMC12943718